Glucotrack’s Implantable CGM Shows Promise in First Human Trial

Glucotrack has announced positive safety and performance results from a first-in-human study of its implantable continuous glucose monitor (CGM), presented at the American Diabetes Association’s 2025 Scientific Sessions. The 10-person trial, involving inpatient monitoring and follow-up after device removal, showed no serious adverse events and a mean absolute relative difference (MARD) of 7.7%, a key accuracy metric.

Unlike traditional CGMs worn on the skin, Glucotrack’s sensor is implanted in the subclavian vein, providing real-time blood glucose readings and avoiding issues like adhesive irritation and sensor lag. 

Glucotrack plans a 30-person, one-year study in Australia and is in talks with the FDA to begin U.S. trials in 2026. If successful, it could compete with Senseonics, currently the only FDA-cleared implantable CGM.

16-07-2025